TCRX
Tscan Therapeutics
$0.77
−$0.03 (−3.27%)Jul 27, 2026
Key metrics
The numbers that frame TCRX today
- Market cap
- $50.19M
- P/E (TTM)
- -0.4
- EV / FCF
- -0.1
- Gross margin
- 100%
- EV / Sales
- 1.1
- ROIC
- -76.9%
- Div yield
- 0%
- Debt / equity
- 1.0
- 52wk Low
- $0.76
- 52wk High
- $2.57
Growth
Revenue and earnings trend for TCRX
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about TCRX
Is Tscan Therapeutics a good buy?
No. Tscan Therapeutics has poor quality and poor momentum. Both signals point to a weaker setup. Growth looks poor. That could put pressure on the long-term business case. We think Tscan Therapeutics is selling at a very high price.
What is the market capitalization of TCRX?
Tscan Therapeutics's market capitalization is $50.19M.
What is the P/E ratio for TCRX stock?
Tscan Therapeutics's current P/E ratio is -0.4.
What is the 52-week high for TCRX stock?
The 52-week high for Tscan Therapeutics is $2.57. The current close of $0.77 is 70.1% below that high.
What is the 52-week low for TCRX stock?
The 52-week low for Tscan Therapeutics is $0.76. The current close of $0.77 is 1.1% above that low.
Does TCRX stock pay dividends?
Tscan Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for TCRX?
Tscan Therapeutics's Debt / Equity ratio is 0.96.